Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 8701

Next Previous
Drug Profile

AZD 8701

Alternative Names: AZD-8701; FOXP3 antisense oligonucleotide; Foxp3 targeted antisense oligonucleotide - AstraZeneca/Ionis Pharmaceuticals; Gen 2.5 cEt-modified ASOs; ION 736; ION-AZ7; IONIS-AZ7-2.5Rx

Latest Information Update: 06 Mar 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ionis Pharmaceuticals
  • Developer AstraZeneca
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action Antisense RNA inhibitors; Regulatory T-lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 02 Mar 2023 Discontinued - Phase-I for Solid tumours (Combination therapy, In the elderly, Late-stage disease, Second-line therapy or greater, In adults) in Canada, France, Spain, USA (IV) (AstraZeneca pipeline, February 2023)
  • 02 Mar 2023 Discontinued - Phase-I for Solid tumours (In the elderly, Late-stage disease, Monotherapy, Second-line therapy or greater, In adults) in USA, Canada, France, Spain (IV) (AstraZeneca pipeline, February 2023)
  • 03 Jun 2022 Pharmacodynamics data from preclinical trials in solid tumours presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top